Jeffrey Simmons Purchases 4,971 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CEO Jeffrey Simmons purchased 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $20.84 on Thursday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 52-week low of $12.40 and a 52-week high of $27.72. The business’s 50-day moving average price is $23.10 and its 200 day moving average price is $23.29. The firm has a market cap of $10.41 billion, a P/E ratio of -41.68, a P/E/G ratio of 2.13 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the company posted $0.37 earnings per share. The business’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Elanco Animal Health by 38.0% during the 1st quarter. Bank of America Corp DE now owns 3,358,215 shares of the company’s stock valued at $80,362,000 after acquiring an additional 924,032 shares during the period. Janus Henderson Group PLC lifted its position in shares of Elanco Animal Health by 4.9% during the 1st quarter. Janus Henderson Group PLC now owns 226,000 shares of the company’s stock valued at $5,413,000 after acquiring an additional 10,600 shares during the period. Arkadios Wealth Advisors lifted its position in shares of Elanco Animal Health by 20.0% during the 1st quarter. Arkadios Wealth Advisors now owns 63,457 shares of the company’s stock valued at $1,519,000 after acquiring an additional 10,589 shares during the period. Amundi lifted its position in shares of Elanco Animal Health by 101.9% during the 1st quarter. Amundi now owns 98,313 shares of the company’s stock valued at $2,353,000 after acquiring an additional 49,608 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Elanco Animal Health by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 9,415 shares of the company’s stock valued at $225,000 after acquiring an additional 3,215 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. KeyCorp lifted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus price target of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.